Process for preparing zolpidem

Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

06664421

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to a process for preparing zolpidem.
BACKGROUND OF THE INVENTION
Zolpidem is a known sedative which has the following structure:
EP 0 251 859 describes a process for preparing zolpidem. The six-step synthesis starting with a bromoacetophenone is a generally laborious method.
A process for preparing compounds analogous to zolpidem in which 2-aminopyridines and corresponding bromoketoamides are reacted is described in the literature (J. of Med. Chem., 1999, Vol. 42, No. 19,3934-3941).
The problem of the present invention is therefore to provide an improved, economical process for preparing zolpidem which can be used on an industrial scale.
DETAILED DESCRIPTION OF THE INVENTION
The present invention solves the problem outlined above by the method of synthesis described hereinafter.
The invention thus relates to a process for preparing a compound of formula (I)
wherein
a compound of formula (II)
wherein
R
1
denotes chlorine, bromine, iodine, —O—COCH
3
, tosylate or mesylate, is reacted with a compound of formula (III),
 optionally in a suitable diluent and/or in the presence of a suitable added reagent or catalyst, characterised in that the reaction is carried out in a temperature range from 20 to 80° C.
In a particularly preferred process a diluent is used which is selected from among acetonitrile, N-methylpyrrolidinone, tetrahydrofuran, acetone, ethanol and dichloromethane.
In another preferred process, acetonitrile is used as the diluent.
According to the invention, a process in which the reaction is carried out at a temperature of about 60 to 75° C., preferably 70° C., is particularly important.
Also preferred is a process in which the compound of formula (II) is used in a molar ratio of 1:1 to 1:3 to the compound of formula (III).
Particularly preferred is a process in which the compound of formula (II) is used in a molar ratio of about 1:1.3 to the compound of formula (III).
Most particularly preferred is a process in which an added reagent and/or catalyst is used which is selected from among p-toluenesulphonic acid monohydrate, sodium hydrogen carbonate, sodium acetate, pyridine, dimethylaminopyridine, magnesium sulphate, triethylamine, trimethylorthoformate and tetrabutylammonium bromide.
The invention further relates to the compound of formula (II)
wherein
R
1
denotes bromine.
The present invention also relates to a process for preparing a compound of formula (II), herein a compound of formula (IV)
is reacted with elemental bromine in a diluent, preferably dichloromethane.
The reaction of a compound of formula (IV) with elemental bromine is generally carried out at a temperature of 10 to 50° C., preferably 15 to 35° C., more preferably 18 to 30° C., most preferably about 20 or 25° C.
The compound of formula IV is generally used in a molar ratio of 1.5:1 to 1:1.5, preferably about 1:1.2, to elemental bromine.
The invention also relates to the use of compounds of formula (II) for preparing pharmaceutically active compounds.
Preferably, the compound of formula (II) is used to prepare zolpidem.
The invention further relates to a process for preparing a compound of formula (I), this process comprising the following steps:
a) reacting the compound of formula (IV) in an organic diluent at a temperature of 30 to 50° C., preferably about 40° C., with elemental bromine.
b) washing the reaction mixture with water,
c) after phase separation, concentrating the organic phase by evaporation and optionally diluting it with another organic diluent, and
d) reacting the concentrated organic phase of a) to c) with the compound of formula (III) at 20 to 80° C., preferably 60 to 75° C., preferably about 70° C., without isolating the intermediate product.
The present invention further relates to the use of the compound of formula (I) for preparing the pharmaceutically acceptable salts thereof.
The compound of formula (I) is preferably used to prepare zolpidem semitartrate.
Acids suitable for forming a salt of the compounds according to the invention include, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, nitric acid, oxalic acid, malonic acid, fumaric acid, maleic acid, tartaric acid, citric acid, ascorbic acid and methanesulphonic acid, particularly tartaric acid.
In a preferred embodiment of the process according to the invention for preparing the compound of formula II, one equivalent of the compound of formula IV is dissolved in a diluent, preferably glacial acetic acid, ethyl acetate, n-butyl acetate or diethylether, most preferably ethyl acetate. A solution of usually 1 to 1.5 equivalents, preferably one equivalent, of bromine is added dropwise in a diluent, preferably ethyl acetate, at a temperature of 40 to 70° C., preferably about 45° C., and stirred for 2 to 24 h, preferably to 15 h, most preferably 12 h, at a temperature of 10 to 50° C., preferably 15 to 35° C., more preferably 18 to 30° C., most preferably about 20 or 25° C. The suspension obtained is filtered, the residue is added to a little water and stirred for about 0.5 to 2 h, preferably about 1 h. The suspension is filtered again and the residue is washed with water. The crystals obtained are dried, preferably in a vacuum drying cupboard at 40 to 80° C., preferably at about 70° C.
In a preferred embodiment of the process according to the invention for preparing the compound of formula I, about 1 equivalent of the compound of formula (II) is placed in a diluent, for example acetonitrile, and a solution of generally 2 equivalents of the compound of general formula (III) and a diluent, for example acetonitrile, is added dropwise at 20 to 80° C., more preferably at 40 to 75° C., most preferably at a temperature of about 70° C. within 0.5 to 3 h, preferably 1 to 2 h, more preferably about 1.5 or 1.75 h. After it has all been added, the mixture is stirred for 2 to 6 h, preferably 2 to 5 h, more preferably about 2.5 to 3 h.
The reaction mixture is then diluted with a diluent, preferably dichloromethane, and washed one to five times, preferably three times, with water. The organic phase is extracted one to five times with hydrochloric acid, preferably 2 N hydrochloric acid. The combined acid phases are adjusted to a pH of between about 7 and 9, preferably to a pH of about 8, using a base, preferably sodium hydroxide solution, more preferably 20% sodium hydroxide solution. After the reaction mixture has been cooled it is extracted one to five times with an organic diluent, selected from among dichloromethane, toluene, ethyl acetate, n-butyl acetate and methyl-tert.-butylether, preferably dichloromethane and ethyl acetate, more preferably ethyl acetate. The combined organic phases are dried, preferably with magnesium sulphate, and concentrated by evaporation. The product which crystallises out is mixed with a little water and stirred for 5 to 20 h, preferably 15 h, and the crystals are filtered off, washed with water and dried, preferably at 30 to 80° C., preferably at 60° C., for 1 to 10 h, preferably 5 h.
In a preferred embodiment of the process according to the invention for preparing the semitartrate salt of the compound of general formula I, generally 2 equivalents of the compound of formula I are placed in a diluent, preferably methanol, ethyl acetate, Isopropanol or ethanol, more preferably methanol, and a solution of 1 equivalent of (2R, 3R)-(+)-tartaric acid in a diluent, preferably methanol, ethanol or isopropanol, more preferably methanol, is added.
A precipitation agent, preferably tert.butylmethylether, an isopropanol/methanol-mixture or a methanol/ether mixture, preferably tert.butylmethylether, is optionally added. The mixture is stirred for 1 to 24 h, preferably 12 h, at a temperature of 15 to 30° C., preferably at about 20 or 25° C. The suspension formed is stirred for a further 0.5 to 3 h, preferably about 1 hour at a temperature of 0 to 20° C., preferably 3 to 10° C., most preferably at about 5° C. The crystals obtained are filtered, optionally washed with a solvent, preferably with tert.butylmethylether, and the cryst

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Process for preparing zolpidem does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for preparing zolpidem, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing zolpidem will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3110663

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.